FDA accounting for FY 1996 spending criticized by Sen. Cochran at May 1 hearing.
This article was originally published in The Tan Sheet
Executive Summary
FDA ACCOUNTING OF FY 1996 SPENDING CRITICIZED by Sen. Thad Cochran (R-Miss.) at a May 1 Senate Appropriations/Agriculture Subcommittee hearing. In requesting an amendment to FDA's FY 1998 budget detailing rent and other office expenses, the subcommittee chairman chastised the agency for giving Congress the "run around" when it inquires how funds are being allocated and for its "callous disregard" of Congress' views when it distributes its monies.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning